Robyn M. Scherber, MD, MPH

Robyn M. Scherber, MD, MPH, a physician at Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, discusses

r advice for treating patients with myelofibrosis

(MF) that become refractory or resistant to ruxolitinib (Jakifi).

Ruxolitinib should be maximized in patients with MF as it is known to have spleen response, symptom response, and patients also tend to feel better on it. Scherber says optimizing ruxolitinib is key. However, she has seen physicians try to dose down at the first sign of concerning anemia. Erythropoietin or danazol can be used to help treat anemia in these patients.

Videos

Robyn M. Scherber, MD, MPH, discusses her advice for treating patients with myelofibrosis that become refractory or resistant to ruxolitinib.

Discussing Options for Ruxolitinib-Refractory Patients With Myelofibrosis

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, addresses the management of patients with myelofibrosis (MF) after failure on ruxolitinib (Jakafi).

Ruxolitinib failure is observed in a broad range of presentations and definitions, and Scherber says that a key difference should specifically be made between ruxolitinib refractory/resistant patients and ruxolitinib progressed/relapsed patients. Scherber says that she evaluates which category a patient falls into once they have failed on ruxolitinib, and then adjusts treatment accordingly.

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, addresses the management of patients with myelofibrosis after failure on ruxolitinib (Jakafi).<br />
&nbsp;

Robyn M. Scherber, MD, MPH | Authors

Articles

Discussing Options for Ruxolitinib-Refractory Patients With Myelofibrosis

Addressing Ruxolitinib Resistance in Myelofibrosis